



MED RX POLICY

- POLICY:** Hyaluronic Acid Derivatives (Intraarticular) Med Rx Policy
- Durolane® (sodium hyaluronate injection – Bioventus)
 - Euflexxa® (sodium hyaluronate injection – Ferring)
 - Gel-One® (sodium hyaluronate injection – Seikagaku/Zimmer)
 - Gelsyn-3™ (sodium hyaluronate injection – Bioventus)
 - GenVisc® 850 (sodium hyaluronate injection – OrthogenRx)
 - Hyalgan® (sodium hyaluronate injection – Fidia/Sanofi)
 - Hymovis® (high molecular weight viscoelastic hyaluronan injection – Fidia)
 - Hymovis® One (high molecular weight viscoelastic hyaluronan injection – Fidia)
 - Monovisc® (high molecular weight hyaluronan injection – Anika)
 - Orthovisc® (high molecular weight hyaluronan injection – Anika)
 - Supartz FX™ (sodium hyaluronate injection – Seikagaku/Bioventus)
 - Sodium hyaluronate 1% injection – Teva
 - SynoJoynt™ (sodium hyaluronate injection – Arthrex)
 - Synvisc® (hylan G-F 20 sodium hyaluronate injection – Genzyme/Sanofi)
 - Synvisc-One® (hylan G-F 20 sodium hyaluronate injection – Genzyme/Sanofi)
 - Triluron® (sodium hyaluronate injection – Fidia)
 - TriVisc® (sodium hyaluronate injection – OrthogenRx)
 - Visco-3™ (sodium hyaluronate injection – Seikagaku/Zimmer)

REVIEW DATE: 10/22/2025; selected revision 02/25/2026

OVERVIEW

Hyaluronic acid derivatives are indicated for the treatment of **pain related to knee osteoarthritis** in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics (e.g., acetaminophen).¹⁻¹⁸ This policy involves the use of the intraarticular hyaluronic acid derivatives used for knee osteoarthritis.

Table 1. Number of Injections per Course of Therapy for Intraarticular Hyaluronic Acid Derivatives.^{1-18*}

| Product | Number of injections per course |
|--|---|
| Durolane, Gel-One, Hymovis One, Monovisc, Synvisc-One | One injection given one time |
| Hymovis | Two injections given 1 week apart |
| Euflexxa, Gelsyn-3, Sodium Hyaluronate, SynoJoynt, Synvisc, Triluron, TriVisc, Visco-3 | Three injections given 1 week apart |
| Orthovisc | Three or four injections given 1 week apart |
| GenVisc 850, Hyalgan, Supartz FX | Five injections given 1 week apart |

* Dose is for one knee. If two knees are being treated, then each knee requires a syringe or vial of product.

POLICY STATEMENT

This Med Rx program has been developed to encourage the use of Preferred Products. For all products (Preferred and Non-Preferred), the patient is required to meet the standard *Hyaluronic Acid Derivatives (Intraarticular) Utilization Management Medical Policy* criteria. The program also directs the patient to try at least two Preferred Products prior to the approval of a Non-Preferred Product. Patients with a history of using a Non-Preferred Product who require additional therapy with a hyaluronic acid derivative

intraarticular product are directed to the Preferred Products. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals are provided for the number of injections required to complete one course of therapy, as noted in the standard *Hyaluronic Acid Derivatives (Intraarticular) Utilization Management Medical Policy*.

Automation: None.

Preferred Products: Monovisc, Orthovisc, Synvisc, Synvisc One

Non-Preferred Products: Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Hymovis One, Supartz FX, Sodium hyaluronate injection, SynoJoynt, Triluron, TriVisc, Visco-3

RECOMMENDED EXCEPTION CRITERIA

| Non-Preferred Products | Exception Criteria |
|---|---|
| Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Hymovis One, Supartz FX, Sodium hyaluronate injection, SynoJoynt, Triluron, TriVisc, Visco-3 | <ol style="list-style-type: none"> 1. Approve one course of therapy per treated knee if the patient meets BOTH of the following (A <u>and</u> B): <ol style="list-style-type: none"> A) Patient meets the standard <i>Hyaluronic Acid Derivatives (Intraarticular) Utilization Management Medical Policy</i> criteria; AND B) Patient meets ONE of the following (i <u>or</u> ii): <ol style="list-style-type: none"> i. Patient tried at least one course of therapy with at least TWO of the following products (a, b, c, <u>or</u> d): <ol style="list-style-type: none"> a) Monovisc (one course equals 1 injection); OR b) Orthovisc (one course equals 3 or 4 injections); OR c) Synvisc (one course equals 3 injections); OR d) Synvisc One (one course equals 1 injection); OR ii. Patient meets BOTH of the following (a <u>and</u> b): <ol style="list-style-type: none"> a) The request is for a product that requires more than one injection to complete a course; AND <u>Note:</u> Examples of products that are given as more than one injection to complete a course include Euflexxa, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Supartz FX, Sodium hyaluronate injection, SynoJoynt, Triluron, TriVisc, or Visco-3. b) Patient has already started a course of injections with one of these agents. <u>Note:</u> If a course of therapy has already been started, the patient can continue with the same product to complete the entire course. After completing this course, if further therapy is required with an intraarticular hyaluronic acid derivative, then Preferred Product(s) must be tried. |

REFERENCES

1. Durolane[®] intraarticular injection [prescribing information]. Durham, NC: Bioventus; not dated.
2. Euflexxa[®] intraarticular injection [prescribing information]. Parsippany, NJ: Ferring; July 2016.
3. Gel-One[®] intraarticular injection [prescribing information]. Warsaw, IN: Zimmer; May 2011.
4. Gelsyn-3[®] intraarticular injection [prescribing information]. Durham, NC: Bioventus; 2016.
5. GenVisc[®] 850 intraarticular injection [prescribing information]. Doylestown, PA: OrthogenRx; not dated.
6. Hyalgan[®] intraarticular injection [prescribing information]. Parsippany, NJ: Fidia Pharma; May 2014.
7. Hymovis[®] intraarticular injection [prescribing information]. Parsippany, NJ: Fidia Pharma; October 2015.
8. Monovisc[®] intraarticular injection [prescribing information]. Bedford, MA: Anika; not dated.
9. Orthovisc[®] intraarticular injection [prescribing information]. Bedford, MA: Anika; September 2014.
10. Sodium hyaluronate 1% intraarticular injection [prescribing information]. North Wales, PA: Teva; March 2019.
11. Supartz[®] FX[™] intraarticular injection [prescribing information]. Durham, NC: Bioventus; April 2015.
12. Synvisc[®] intraarticular injection [prescribing information]. Ridgefield, NJ: Genzyme; September 2014.
13. Synvisc-One[®] intraarticular injection [prescribing information]. Ridgefield, NJ: Genzyme; September 2014.
14. Triluron intraarticular injection [prescribing information]. Florham Park, NJ: Fidia Pharma; March 2019.
15. Trivisc intraarticular injection [prescribing information]. Doylestown, PA: OrthogenRx; not dated.
16. Visco-3 intraarticular injection [prescribing information]. Durhan, NC: Bioventus; not dated.
17. SynoJoynt[™] injection [prescribing information]. Naples, FL: Arthrex; 2022.
18. Hymovis[®] One injection [prescribing information]. Florham Park, NJ: Fidia; 2025

HISTORY

| Type of Revision | Summary of Changes | Review Date |
|-------------------|---|-------------|
| Annual Revision | No criteria changes. | 09/27/2023 |
| Annual Revision | No criteria changes. | 10/09/2024 |
| Annual Revision | No criteria changes. | 10/22/2025 |
| Selected Revision | Hymovis One was added as a Non-Preferred. The same exceptions apply as the other Non-Preferred. | 02/25/2026 |